Quarterly Result16 Jan 2026, 07:51 pm
Eiko Lifesciences Ltd Schedules Board Meeting to Approve Q3 Financial Results of FY2025-2026
AI Summary
Eiko Lifesciences Ltd has informed the BSE that the company's Board of Directors will meet on 29th January 2026 to consider and approve the Unaudited Standalone and Consolidated Financial Results for the quarter ending on 31st December 2025. The Trading Window for dealing in securities of the Company for all Designated Persons has been closed since 1st January 2026 and will remain closed for 48 hours after the declaration of the Unaudited Financial Results.
Key Highlights
- Eiko Lifesciences Ltd schedules Board Meeting on 29th January 2026 to approve Q3 FY2025-2026 Financial Results
- The meeting will consider and approve Unaudited Standalone and Consolidated Financial Results for the quarter ending on 31st December 2025
- Trading Window for dealing in securities of the Company for all Designated Persons is closed since 1st January 2026
- Trading Window to remain closed for 48 hours after the declaration of the Unaudited Financial Results
Price Impact
More from EIKO